Evaluation of the BioPlex™ 2200 ANA Screen: Analysis of 510 Healthy Subjects: Incidence of Natural/Predictive Autoantibodies
The DOI matches its Crossref record.
Abstract
A bstract: The BioPlex™ 2200 ANA Screen is a fully automated system that determines levels for 13 different autoimmune antibodies of established clinical significance. The objective of this study was to determine the specificity of the BioPlex™ 2200 ANA Screen assay and to analyze the antibody profile samples collected from healthy subjects against comparative ELISA and IIF screening methods. A total of 510 specimens were randomly selected from a cohort of apparently healthy blood bank donors. Samples were distributed to five age brackets. All samples were tested using Bio‐Rad's ANA Screen kit. Specificity was compared to IIF and ELISA results. Most of the samples were found negative in all ANA screening systems (84.5% by IIF, 92.5% by BioPlex™ 2200 ANA Screen kit, and 94.5% by ELISA). The frequency of positive results was highest (15.5%) using IIF, in comparison to almost similar results (5.5% vs. 7.5%) achieved by ANA ELISA and BioPlex™ 2200 ANA Screen kits. The positive rate of autoantibodies was significantly reduced when analyzed by different combinations of ANA screen assays (from 2.35% using IIF + BioPlex ANA Screen tests to 0.98% by using all three tests). Using the BioPlex™ 2200 ANA Screen system, we were able to identify samples with high levels of individual antibodies: anti‐dsDNA at 20‐63/IU/mL, antichromatin at 4–8 AI, anti‐SmRNP at 2–6 AI, and anti‐RNPA at 2‐4.5 AI. Importantly, from 7 IIF and ELISA positive sera, 5 of these were also BioPlex 2200 positive, suggesting that the BioPlex is seeing the samples that are of the greatest interest, using the established techniques. The specificity of the BioPlex 2200 ANA Screen analysis of 13 different analytes (dsDNA, centromere B, chromatin, Jo1, ribosomal P, RNP 68, RNP A, Scl‐70, Sm, SmPNP, SS‐A52, SS‐A60, SS‐B) is comparable (P < 0.252) to the ELISA ANA screening test. Like the ELISA, the BioPlex 2200 has a lower (P < 0.001) positive rate than IIF for the autoantibody screening.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Multiplexed protein measurement: technologies and applications of protein and antibody arrays
Kingsmore, S. F. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2006 · Cited by 715
Advances and applications of multiplexed diagnostic technologies in autoimmune diseases
Fritzler, M. (2006) · Lupus · doi:10.1191/0961203306lu2327oa · Cited by 78
Infantino, M., Meacci, F., Bentow, C., Martis, P., Benucci, M., Afeltra, A., Rigon, A., Atzeni, F., Sarzi-Puttini, P., Manfredi, M., et al. (2015) · Journal of Immunology Research · doi:10.1155/2015/902821 · Cited by 41
Bentow, C., Lakos, G., Martis, P., Wahl, E., Garcia, M., Viñas, O., Espinosa, G., Cervera, R., Sjöwall, C., Carmona-Fernandes, D., et al. (2016) · Lupus · doi:10.1177/0961203316640917 · Cited by 37
Laboratory evaluation of anti-dsDNA antibodies.
Cockx, M., Van Hoovels, L., De Langhe, E., Lenaerts, J., Thevissen, K., Persy, B., Bonroy, C., Vercammen, M., & Bossuyt, X. (2022) · Clinica Chimica Acta · doi:10.1016/j.cca.2021.12.029 · Cited by 30
Metadata
- Authors
- SHOVMAN, O., GILBURD, B., BARZILAI, O., SHINAR, E., LARIDA, B., ZANDMAN‐GODDARD, G., BINDER, S. R., & SHOENFELD, Y.
- Venue
- Annals of the New York Academy of Sciences
- Publisher
- Wiley
- Published
- 2005-06
- Volume
- 1050
- Issue
- 1
- Pages
- 380-388
- ISSN
- 0077-8923 (ISSN-L)
- 1749-6632
- OpenAlex
- W1974492781
- Cited by
- 114
- References
- 0
- FWCI
- 5.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evaluation of the BioPlex™ 2200 ANA Screen: Analysis of 510 Healthy Subjects: Incidence of Natural/Predictive Autoantibodies. https://app.cochat.ai/papers/10.1196/annals.1313.120
- The paper
- SHOVMAN, O., GILBURD, B., BARZILAI, O., SHINAR, E., LARIDA, B., ZANDMAN‐GODDARD, G., BINDER, S. R., & SHOENFELD, Y. (2005). Evaluation of the BioPlex™ 2200 ANA Screen: Analysis of 510 Healthy Subjects: Incidence of Natural/Predictive Autoantibodies. Annals of the New York Academy of Sciences. https://doi.org/10.1196/annals.1313.120
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.